title: Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.
abstract: HER2 amplification and/or expression occurs in gastric carcinoma (GC), but the role of HER2 in the prognosis of GC remains unclear. The dysregulation of transforming acidic coiled coil 1 (TACC1), a downstream gene of HER2, is thought to be involved in the development of GC. The aim of this study was to investigate the role and relationship of HER2 and TACC1 in GC. The expression of HER2 and TACC1 was analyzed using immunohistochemistry on 129 primary resected GC patients, and HER2 amplification was additionally determined by FISH. The data on clinicopathological features and relevant prognostic factors in these patients were analyzed. The expression (3+, 2+ and 1+) and the amplification of HER2 was observed in 57 cases (44.2 %) and 25 cases (19.4 %), respectively, and the correlation between HER2 expression and amplification was strong (p < 0.001). According to the FDA criteria, 24 cases (18.6 %) would have been considered as HER2 positive. A total 62 (48.1 %) GC tissues showed positive cytoplasmic staining of TACC1. There was a significant and positive association between TACC1 and HER2. HER2 positive was significantly associated with TNM stage (p = 0.019), and TACC1 expression was significantly associated with lymph node metastasis (p = 0.004) and TNM stage (p = 0.004). TNM stage, TACC1 expression and co-positive of both HER2 and TACC1 were independent prognostic factors. TACC1 expression is an independent prognostic indicator of GC. The correlation between TACC1 expression and HER2-positive status indicated a possible synergistic regulation of the two molecules and co-positive of both HER2 and TACC1 maybe a more valuable prognostic marker.
authors.affiliation: Department of Oncology, Affiliated Hospital of Medical College, Qingdao University, 16 Jiangsu Road, Qingdao, 266003, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Lv
authors.forename: Ya-sai
authors.initials: YS
authors.lastname: Yao
authors.forename: Fei
authors.initials: F
authors.lastname: Zhou
authors.forename: Li-kun
authors.initials: LK
authors.lastname: Zhuang
authors.forename: Ru-yong
authors.initials: RY
authors.lastname: Yao
authors.forename: Jun
authors.initials: J
authors.lastname: Liang
authors.forename: Wen-sheng
authors.initials: WS
authors.lastname: Qiu
authors.forename: Lu
authors.initials: L
authors.lastname: Yue
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D005260:Female; D005326:Fetal Proteins / Q000096:biosynthesis*; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D009687:Nuclear Proteins / Q000096:biosynthesis*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality; D015996:Survival Rate / Q000639:trends
chemical_list: D014408:Biomarkers, Tumor; D005326:Fetal Proteins; D008869:Microtubule-Associated Proteins; D009687:Nuclear Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C120584:TACC1 protein, human; C508053:ERBB2 protein, human